Enliven therapeutics announces proposed public offering of common stock and pre-funded warrants

Boulder, colo. , june 13, 2025 /prnewswire/ -- enliven therapeutics, inc. (enliven or the company) (nasdaq: elvn), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of enliven's common stock.
ELVN Ratings Summary
ELVN Quant Ranking